Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Canopy Growth Corp (CGC) Price & Performance

BioNTech SE - ADRTrade
Canopy Growth CorpTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Canopy Growth Corp — how do they compare? BioNTech SE - ADR trades at $93.06 (market cap $23.31B), while Canopy Growth Corp trades at $1.03 (market cap $421.10M). The key difference: BioNTech SE - ADR is far larger — about 55.4× Canopy Growth Corp's market cap. Which is the better fit depends on your goals.

BNTXCGC
Market Cap
$23.31B$421.10M
Sector
HealthHealth
52-Week High
$119.34$1.92
52-Week Low
$83.89$0.86
Enterprise Value
$6.60B$378.55M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

Canopy Growth Corp

Canopy Growth (CGC) trades at $1.02, up 7.13% with a bullish technical signal. The company reported Q1 fiscal 2027 revenue growth of 13% to C$81.2 million and narrowed its EBITDA loss. While revenue trends show stabilization after declining from $520M in 2022 to $269M in 2025, the company continues to post significant net losses with a -222.36% margin. The balance sheet shows improvement with debt-to-asset ratio declining from 53.61% in 2023 to 33.13% in 2025.

CGC presents a high-risk opportunity with potential catalysts from cannabis rescheduling and European expansion. The stock trades below book value (P/B 0.86) but faces substantial execution risks amid persistent losses. Analyst sentiment is mixed with 33% buy ratings, reflecting optimism about restructuring progress versus concerns about profitability timeline.

Returns comparison

Trailing returns across standard periods

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Canopy Growth Corp

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.

Read more on CGC